Filtered By:
Therapy: Antiviral Therapy

This page shows you your search results in order of date. This is page number 6.

Order by Relevance | Date

Total 305 results found since Jan 2013.

Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infection
Antiviral Res. 2022 May 4:105329. doi: 10.1016/j.antiviral.2022.105329. Online ahead of print.ABSTRACTSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19 pandemic, has infected over 260 million people over the past 2 years. Remdesivir (RDV, VEKLURY®) is currently the only antiviral therapy fully approved by the FDA for the treatment of COVID-19. The parent nucleoside of RDV, GS-441524, exhibits antiviral activity against numerous respiratory viruses including SARS-CoV-2, although at reduced in vitro potency compared to RDV in most assays. Here we find in both human alveolar an...
Source: Antiviral Research - May 7, 2022 Category: Virology Authors: Jared Pitts Darius Babusis Meghan S Vermillion Raju Subramanian Kim Barrett Diane Lye Bin Ma Xiaofeng Zhao Nicholas Riola Xuping Xie Adriana Kajon Xianghan Lu Roy Bannister Pei-Yong Shi Maria Toteva Danielle P Porter Bill J Smith Tomas Cihlar Richard Mack Source Type: research

Viruses, Vol. 14, Pages 976: Activity of a Carbohydrate-Binding Module Therapy, Neumifil, against SARS-CoV-2 Disease in a Hamster Model of Infection
wat Stuart Dowall The rapid global spread of severe acute respiratory coronavirus 2 (SARS-CoV-2) has resulted in an urgent effort to find efficacious therapeutics. Broad-spectrum therapies which could be used for other respiratory pathogens confer advantages, as do those based on targeting host cells that are not prone to the development of resistance by the pathogen. We tested an intranasally delivered carbohydrate-binding module (CBM) therapy, termed Neumifil, which is based on a CBM that has previously been shown to offer protection against the influenza virus through the binding of sialic acid receptors. Using th...
Source: Viruses - May 6, 2022 Category: Virology Authors: Rachel Fell Jane A. Potter Samantha Yuille Franscisco J. Salguero Robert Watson Didier Ngabo Karen Gooch Roger Hewson David Howat Stuart Dowall Tags: Article Source Type: research

Viruses, Vol. 14, Pages 841: Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity
ias In RNA viruses, a small increase in their mutation rates can be sufficient to exceed their threshold of viability. Lethal mutagenesis is a therapeutic strategy based on the use of mutagens, driving viral populations to extinction. Extinction catastrophe can be experimentally induced by promutagenic nucleosides in cell culture models. The loss of HIV infectivity has been observed after passage in 5-hydroxydeoxycytidine or 5,6-dihydro-5-aza-2′-deoxycytidine while producing a two-fold increase in the viral mutation frequency. Among approved nucleoside analogs, experiments with polioviruses and other RNA ...
Source: Viruses - April 18, 2022 Category: Virology Authors: Ikbel Hadj Hassine Manel Ben M ’hadheb Luis Men éndez-Arias Tags: Review Source Type: research

Remdesivir in Coronavirus Disease 2019 patients treated with anti-CD20 monoclonal antibodies: a case series
ConclusionsWe observed a benefit of antiviral therapy in a majority of COVID-19 patients on anti-CD20 treatment, without any clinical relapses in the 1-year follow-up. Although these data suggest that remdesivir might be a promising management option in patients with delayed viral clearance, the lack of a control group is an important limitation of the study design.Trial registrationEthikkommission Ostschweiz, Scheibenackerstrasse 4, CH-9000 St. Gallen approved this case series. Project-ID 2021-00349 EKOS 21/027.
Source: Infection - April 15, 2022 Category: Infectious Diseases Source Type: research

Herpes Simplex Virus 1 Anterior Uveitis following Coronavirus Disease 2019 (COVID-19) Vaccination in an Asian Indian Female
CONCLUSION: This report demonstrates a potential association of HSV 1 anterior uveitis with COVID-19 vaccination. A high index of suspicion of viral etiology is warranted when uveitis presents with reduced corneal sensations and pigmented keratic precipitates, following a recent history of COVID-19 vaccination.PMID:35404741 | DOI:10.1080/09273948.2022.2055580
Source: Ocular Immunology and Inflammation - April 11, 2022 Category: Allergy & Immunology Authors: Rohini Sangoram Padmamalini Mahendradas Sai Bhakti Mishra Ankush Kawali Srinivasan Sanjay Rohit Shetty Source Type: research

A Case of Heart Transplantation for Fulminant Myocarditis After ChAdOx1 nCoV-19 Vaccination
J Korean Med Sci. 2022 Apr 4;37(13):e104. doi: 10.3346/jkms.2022.37.e104.ABSTRACTVaccines have become the mainstay of management against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (coronavirus disease 2019; COVID-19) in the absence of effective antiviral therapy. Various adverse effects of COVID-19 vaccination have been reported, including cardiovascular complications such as myocarditis or pericarditis. Herein, we describe clinical records of a 63-year woman with fulminant myocarditis following ChAdOx1 nCoV-19 vaccination that was salvaged by heart transplantation. She complained chest pain, na...
Source: Journal of Korean Medical Science - April 5, 2022 Category: Biomedical Science Authors: Seok Hyun Kim Soo Yong Lee Ga Yun Kim Ji Soo Oh Jeongsu Kim Kook Jin Chun Min Ho Ju Chee-Hoon Lee Yeo-Jeong Song Joo-Young Na Source Type: research